28/8/2025
AKIGAI Welcomes Strategic Investment Partner!
AKIGAI has secured a strategic partnership with investor Brynjar Forbergskog
21/11/2024
FDA grants Orphan Designation for the treatment of CRPS with AKI-007
Dramatic, durable and safe pain relief in chronic CRPS patients has lead to this milestone. A phase III trial is the next step.
14/8/2024
Orphan Designation
AKIGAI is excited that we were granted an Orphan Designation from the EMA for the treatment of CRPS with our 1st generation EGFR inhibitor tablet.